Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06393738 · ClinicalTrials.gov registry record · Phase 1
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
A Phase 1 study of Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) and Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL), sponsored by Arvinas.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 255
- Enrollment target
- 17
- Study locations
NCT06393738: Recruiting Phase 1 study of Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) and Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL), sponsored by Arvinas.
NCT06393738 is a Phase 1 study of Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) and Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) that is actively recruiting participants, run by Arvinas. The registered enrollment target is 255 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (325% higher). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06393738, a Phase 1 study of Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) and Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL), is actively recruiting participants, sponsored by Arvinas.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 255 participants
- Enrollment target
- 17
- Study locations
Study Summary
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
Primary Outcome
Percentage of participants in dose escalation arm at a given dose cohort with AEs meeting protocol defined dose limiting toxicities during cycle 1 (28 days)
Conditions Studied
Interventions
- DRUG Glofitamab
- DRUG ARV-393
Study Locations (17)
Other
- Clinical Trial Site - Copenhagen
- Clinical Trial Site - Odense C
- Clinical Trial Site - Barcelona
- Clinical Trial Site - Madrid
- Clinical Trial Site - Salamanca
New York
- Clinical Trial Site - New York
- Clinical Trial Site - New York
Connecticut
- Clinical Trial Site - New Haven
Michigan
- Clinical Trial Site - Detroit
New Jersey
- Clinical Trial Site - New Brunswick
Ohio
- Clinical Trial Site - Cleveland
Tennessee
- Clinical Trial Site - Nashville
Texas
- Clinical Trial Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2024-09-05 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
What NCT06393738 shows while recruiting
NCT06393738 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (325% higher).
The record links to 2 conditions, with Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) appearing as the primary indexed condition, and to 2 interventions - of which Glofitamab is the first listed.
NCT06393738 lists 17 locations in 12 states (Other, New York, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06393738 about?
NCT06393738 is a clinical study titled "A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.". This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by b...
What is the current status of trial NCT06393738?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 255 participants. The study started on 2024-09-05. Estimated completion is 2028-03.
What conditions does trial NCT06393738 study?
This clinical trial studies the following conditions: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL).
What interventions are being tested in trial NCT06393738?
The interventions under investigation include: Glofitamab (DRUG), ARV-393 (DRUG).
Who is sponsoring clinical trial NCT06393738?
This trial is sponsored by Arvinas, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06393738 being conducted?
This trial has 17 study locations across Connecticut, Michigan, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06393738's enrollment target sits among peer trials
255 168th of 2000 higher than 1,833 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI